According to a recent LinkedIn post from Visby Medical, the company is seeing strong traction from its partnership with DoorDash around at-home PCR sexual health tests. The post cites month-over-month demand growth ranging from 50% to 150% and describes DoorDash as an increasingly important distribution channel.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post indicates that Visby’s test is expected to be available in nearly 2,000 U.S. ZIP codes within two weeks, targeting roughly 15–20% of middle-to-high-income households, with delivery times as short as 30 minutes. This expanded geographic and demographic reach could support higher test volumes and greater brand visibility in the direct-to-consumer diagnostics market.
Customer engagement metrics highlighted in the post include a 4.8-star average rating, a Net Promoter Score above 70, and a claim that DoorDash users are twice as likely to purchase compared with other channels. If sustained, these indicators may point to favorable unit economics for this channel and validate the on-demand delivery model for sensitive health products.
The post also references collaborations with Everlywell and Google Cloud, positioning these relationships as part of a broader push to expand access to “lab-quality” STI testing. For investors, the combination of rapid channel growth, positive user feedback, and strategic partnerships suggests potential for Visby to strengthen its competitive position in at-home diagnostics, although revenue impact and scalability are not quantified in the post.